Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2013, Article ID 368751, 12 pages
http://dx.doi.org/10.1155/2013/368751
Review Article

Tissue Banking, Bioinformatics, and Electronic Medical Records: The Front-End Requirements for Personalized Medicine

1The Genomics and Biomarkers Program, The John Theurer Cancer Center at Hackensack, University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
2Sophic Systems Alliance Inc., 20271 Goldenrod Lane, Germantown, MD 20876, USA
3Siemens Corporate Research, IT Platforms, Princeton, NJ 08540, USA
4Research for the Cure Foundation, Hillsdale, NJ 07642, USA

Received 7 February 2013; Revised 3 May 2013; Accepted 7 May 2013

Academic Editor: Thomas E. Adrian

Copyright © 2013 K. Stephen Suh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. de Souza and O. I. Olopade, “CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine,” Seminars in Oncology, vol. 38, no. 2, pp. 263–273, 2011. View at Publisher · View at Google Scholar
  2. Early Breast Cancer Trialists' Collaborative Group, “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005. View at Google Scholar
  3. M. Verma, “Personalized medicine and cancer,” Journal of Personalized Medicine, vol. 2, no. 1, pp. 1–14, 2012. View at Publisher · View at Google Scholar
  4. M. Dammann and F. Weber, “Personalized medicine: caught between hope, hype and the real world,” Clinics, vol. 67, supplement 1, pp. 91–97, 2012. View at Google Scholar
  5. A. J. Atherly and D. R. Camidge, “The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers,” British Journal of Cancer, vol. 106, no. 6, pp. 1100–1106, 2012. View at Publisher · View at Google Scholar
  6. S. Louca, “Personalized medicine—a tailored health care system: challenges and opportunities,” Croatian Medical Journal, vol. 53, no. 3, pp. 211–213, 2012. View at Publisher · View at Google Scholar
  7. K. S. Suh, “Discovery of novel biomarkers for the development of personalized medicine,” Translational Medicinecinec, 2012. View at Publisher · View at Google Scholar
  8. A. Somasunderam and D. G. Gorenstein, “Aptamers as novel reagents for biomarker discovery applications,” Translational Medicinec, 2011. View at Publisher · View at Google Scholar
  9. S. K. Suh, Y. K. Remache, J. S. Patel et al., “Informatics-guided procurement of patient samples for biomarker discovery projects in cancer research,” Cell and Tissue Banking, vol. 10, no. 1, pp. 43–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Sarojini, A. Tamir, H. Lim et al., “Early detection biomarkers for ovarian cancer,” Journal of Oncology, vol. 2012, Article ID 709049, 15 pages, 2012. View at Publisher · View at Google Scholar
  11. N. B. la Thangue and D. J. Kerr, “Predictive biomarkers: a paradigm shift towards personalized cancer medicine,” Nature Reviews Clinical Oncology, vol. 8, no. 10, pp. 587–596, 2011. View at Publisher · View at Google Scholar
  12. D. Slamon, W. Eiermann, N. Robert et al., “Adjuvant trastuzumab in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 365, no. 14, pp. 1273–1283, 2011. View at Publisher · View at Google Scholar
  13. A. T. Shaw, U. Yasothan, and P. Kirkpatrick, “Crizotinib,” Nature Reviews Drug Discovery, vol. 10, no. 12, pp. 897–898, 2011. View at Publisher · View at Google Scholar
  14. M. S. Kies and P. M. Harari, “Cetuximab (imclone/merck/bristol-myers squibb),” Current Opinion in Investigational Drugs, vol. 3, no. 7, pp. 1092–1100, 2002. View at Google Scholar
  15. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. B. Chapman, A. Hauschild, C. Robert et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2507–2516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. J. Isakoff, B. Overmoyer, N. M. Tung et al., “A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer,” Journal of Clinical Oncology, vol. 28, supplement 15, 2010. View at Google Scholar
  18. C. M. Annunziata and S. E. Bates, “PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer,” F1000 Biology Reports, vol. 2, no. 1, article 10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. R. S. Herbst, D. Prager, R. Hermann et al., “TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5892–5899, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Giaccone, R. S. Herbst, C. Manegold et al., “Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 777–784, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. Soignet, P. Maslak, Z. G. Wang et al., “Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide,” The New England Journal of Medicine, vol. 339, no. 19, pp. 1341–1348, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. U. Rix, O. Hantschel, G. Dürnberger et al., “Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets,” Blood, vol. 110, no. 12, pp. 4055–4063, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. C. Müller, J. E. Cortes, D. W. Kim et al., “Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations,” Blood, vol. 114, no. 24, pp. 4944–4953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Fischer, R. M. Stone, D. J. DeAngelo et al., “Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4339–4345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Sartore-Bianchi, M. Delorenzi, T. Gagnon-Kugler et al., “New frontiers in therapeutic resistance in cancer,” Expert Review of Anticancer Therapy, vol. 12, no. 7, pp. 877–879, 2012. View at Publisher · View at Google Scholar
  26. C. Fausel, “Targeted chronic myeloid leukemia therapy: seeking a cure,” American Journal of Health-System Pharmacy, vol. 64, supplement 24, pp. S9–S15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. R. Chamarthy, S. C. Williams, and R. M. Moadel, “Lymphoma: radioimmunotherapy of non-hodgkin’s: from the “Magic Bullets” to ‘Radioactive Magic Bullets’,” Journal of Biology and Medicin, vol. 84, pp. 391–407, 2011. View at Google Scholar
  28. F. Lansigan, D. M. Stearns, and F. Foss, “Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma,” Cancer Management and Research, vol. 2, no. 1, pp. 53–59, 2010. View at Google Scholar · View at Scopus
  29. A. Younes, N. L. Bartlett, J. P. Leonard, and D. A. Kennedy, “Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas,” The New England Journal of Medicine, vol. 363, pp. 1812–1821, 2010. View at Google Scholar
  30. S. Zhou, “Clinical pharmacogenomics of thiopurine S-methyltransferase,” Current Clinical Pharmacology, vol. 1, no. 1, pp. 119–128, 2006. View at Google Scholar · View at Scopus
  31. R. Largillier, M. Etienne-Grimaldi, J. Formento et al., “Pharmacogenetics of capecitabine in advanced breast cancer patients,” Clinical Cancer Research, vol. 12, pp. 5496–5502, 2006. View at Google Scholar
  32. C. J. Fabian, “The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer,” International Journal of Clinical Practice, vol. 61, no. 12, pp. 2051–2063, 2007. View at Google Scholar
  33. S. K. McBrayer, M. Yarrington, J. Qian et al., “Integrative gene expression profiling reveals G6PD mediated resistance to RNA directed nucleoside analogues in B-cell neoplasms,” PLoS One, vol. 7, no. 7, Article ID e41455, 2012. View at Google Scholar
  34. L. Yang, H. Tseng, C. Lin et al., “Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients,” Journal of Breast Cancer, vol. 15, no. 3, pp. 288–295, 2012. View at Publisher · View at Google Scholar
  35. M. Milani, G. Jha, and D. A. Potter, “Anastrozole use in early stage breast cancer of post-menopausal women,” Clinical Medicine Therapeutics, vol. 1, pp. 141–156, 2009. View at Google Scholar
  36. S. A. Garnett, M. Martin, G. Jerusalem et al., “Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology,” Breast Cancer Research and Treatment, vol. 138, pp. 149–155, 2013. View at Publisher · View at Google Scholar
  37. X. Liu, D. Cheng, Q. Kuang, G. Liu, and W. Xu, “Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in caucasians,” PLOS One, vol. 8, no. 3, Article ID e58489, 2013. View at Google Scholar
  38. K. R. Fareed, A. Al-Attar, I. N. Soomro et al., “Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy,” British Journal of Cancer, vol. 102, no. 11, pp. 1600–1607, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Li, W. H. Wood, K. G. Becker, A. T. Weeraratna, and P. J. Morin, “Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells,” Oncogene, vol. 26, no. 20, pp. 2860–2872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Yuan, J. Zhang, H. Wang et al., “6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT,” Cancer Research, vol. 71, no. 5, pp. 1904–1911, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. R. S. Finn, J. Dering, D. Conklin et al., “PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro,” Breast Cancer Research, vol. 11, no. 5, article R77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. B. Martin and P. S. Nelson, “From genomics to proteomics: techniques and applications in cancer research,” Trends in Cell Biology, vol. 11, no. 11, pp. S60–S65, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. E. S. Richmond and D. Dunn, “Biomarkers: an overview for oncology nurses,” Seminars in Oncology Nursing, vol. 28, no. 2, pp. 87–92, 2012. View at Publisher · View at Google Scholar
  44. R. Christianson, “Virtual Patient Encounters Aim to Educate Students in Geriatric Care,” The University of Texas, School of Health Information Sciences at Houston, 2009http://www.uthouston.edu/sbmi/story.htm?id=1852714.
  45. A. Gorini, A. Gaggioli, C. Vigna, and G. Riva, “A second life for eHealth: prospects for the use of 3-D virtual worlds in clinical psychology,” Journal of Medical Internet Research, vol. 10, no. 3, article e21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. London Medical Students Train in Second Life Virtual Hospital, iHealthBeat, 2008, http://www.ihealthbeat.org/Articles/2009/3/30/London-Medical-Students-Train-in-Second-Life-Virtual-Hospital.aspx.
  47. C. M. Simon, J. L'Heureux, J. C. Murray et al., “Active choice but not too active: public perspectives on biobank consent models,” Genetics in Medicine, vol. 13, pp. 821–831, 2011. View at Publisher · View at Google Scholar
  48. L. M. Beskow, J. Y. Friedman, N. Chantelle Hardy, L. Lin, and K. P. Weinfurt, “Developing a simplified consent form for biobanking,” PLoS One, vol. 5, no. 10, Article ID e13302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Sarojini, A. Goy, A. Pecora, and K. S. Suh, “Proactive biobanking to improve research and health care,” Journal of Tissue Science & Engineering, vol. 3, no. 2, 2011. View at Google Scholar
  50. M. Galvagni, S. Cotrupi, and M. Barbareschi, “Biobanks and information technology,” Pathologica, vol. 100, no. 2, pp. 116–138, 2008. View at Google Scholar · View at Scopus
  51. C. Voegele, S. V. Tavtigian, D. de Silva, S. Cuber, A. Thomas, and F. le Calvez-Kelm, “A Laboratory Information Management System (LIMS) for a high throughput genetic platform aimed at candidate gene mutation screening,” Bioinformatics, vol. 23, no. 18, pp. 2504–2506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Ölund, P. Lindqvist, and J. E. Litton, “BIMS: an information management system for biobanking in the 21st century,” IBM Systems Journal, vol. 46, no. 1, pp. 171–182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Bevilacqua, F. Bosman, T. Dassesse et al., “The role of the pathologist in tissue banking: European consensus expert group report,” Virchows Archiv, vol. 456, no. 4, pp. 449–454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. P. H. Riegman, M. M. Morente, F. Betsou et al., “Biobanking for better healthcare,” Molecular Oncology, vol. 2, no. 3, pp. 213–222, 2008. View at Publisher · View at Google Scholar
  55. C. T. Scott, T. Caulfield, E. Borgelt et al., “Personal medicine—the new banking crisis,” Nature Biotechnology, vol. 30, no. 2, pp. 141–147, 2012. View at Publisher · View at Google Scholar
  56. Institute of Medicine, Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development: Workshop Summary, National Academies Press, Washington, DC, USA, 2011.
  57. V. P. Scholtes, J. P. de Vries, L. M. Catanzariti et al., “Biobanking in atherosclerotic disease, opportunities and pitfalls,” Current Cardiology Reviews, vol. 7, no. 1, pp. 9–14, 2011. View at Publisher · View at Google Scholar
  58. P. Hainaut, E. Caboux, G. Bevilacqua et al., “Pathology as the cornerstone of human tissue banking: European consensus expert group report,” Biopreservation and Biobanking, vol. 7, no. 3, pp. 157–160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. R. E. Hewitt, “Biobanking: the foundation of personalized medicine,” Current Opinion in Oncology, vol. 23, no. 1, pp. 112–119, 2011. View at Publisher · View at Google Scholar
  60. S. Ogino, C. S. Fuchs, and E. Giovannucci, “How many molecular subtypes? Implications of the unique tumor principle in personalized medicine,” Expert Review of Molecular Diagnostics, vol. 12, no. 6, pp. 621–628, 2012. View at Publisher · View at Google Scholar
  61. S. Pakhomov, S. Bjornsen, P. Hanson, and S. Smith, “Quality performance measurement using the text of electronic medical records,” Medical Decision Making, vol. 28, no. 4, pp. 462–470, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. J. C. Denny, R. A. Miller, L. R. Waitman, M. A. Arrieta, and J. F. Peterson, “Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor,” International Journal of Medical Informatics, vol. 78, supplement 1, pp. S34–S42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. C. L. Overby, P. Tarczy-Hornoch, J. I. Hoath, I. J. Kalet, and D. L. Veenstra, “Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support,” BMC Bioinformatics, vol. 11, no. 9, article S10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. eHealth for a healthier Europehttp://www.ortivus.se/Documents/Pdf/Swedish-EU-Presidency-Report-eHealth-for-a-Healthier-Europe.pdf.
  65. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease, http://www.ucsf.edu/sites/default/files/legacy_files/documents/new-taxonomy.pdf.
  66. A. L. Terry, J. B. Brown, L. Bestard Denomme, A. Thind, and M. Stewart, “Perspectives on electronic medical record implementation after two years of use in primary health care practice,” The Journal of the American Board of Family Medicine, vol. 25, pp. 522–527, 2012. View at Publisher · View at Google Scholar
  67. P. M. Blake, D. A. Decker, T. M. Glennon et al., “Toward an integrated knowledge environment to support modern oncology,” The Cancer Journal, vol. 17, no. 4, pp. 257–263, 2011. View at Publisher · View at Google Scholar
  68. J. L. Bernat, “Ethical and quality pitfalls in electronic health records,” Neurology, vol. 80, no. 11, pp. 1057–1061, 2013. View at Publisher · View at Google Scholar
  69. E. J. Layman, “Ethical issues and the electronic health record,” Health Care Manager, vol. 27, no. 2, pp. 165–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. T. H. Payne, M. Perkins, R. Kalus, and D. Reilly, “The transition to electronic documentation on a teaching hospital medical service,” Annual Symposium Proceedings, vol. 2006, pp. 629–633, 2006. View at Google Scholar · View at Scopus
  71. B. Malin and E. Airoldi, “Confidentiality preserving audits of electronic medical record access,” Studies in Health Technology and Informatics, vol. 129, part 1, pp. 320–324, 2007. View at Google Scholar
  72. C. F. Snyder, A. W. Wu, R. S. Miller, R. E. Jensen, E. T. Bantug, and A. C. Wolff, “The role of informatics in promoting patient-centered care,” The Cancer Journal, vol. 17, no. 4, pp. 211–218, 2012. View at Google Scholar
  73. D. J. Crichton, C. A. Mattmann, M. Thornquist et al., “Bioinformatics: biomarkers of early detection,” Cancer Biomarker, vol. 9, no. 1–6, pp. 511–530, 2010. View at Google Scholar
  74. D. Kihara, Y. D. Yang, and T. Hawkins, “Bioinformatics resources for cancer research with an emphasis on gene function and structure prediction tools,” Cancer Informatics, vol. 2, no. 1, pp. 25–35, 2006. View at Google Scholar · View at Scopus
  75. E. S. Richmond and D. Dunn, “Biomarkers: an overview for oncology nurses,” Seminars in Oncology Nursing, vol. 28, no. 2, pp. 87–92, 2012. View at Publisher · View at Google Scholar
  76. H. Nakagawa, “Research and development for cancer biomarker,” Nippon Rinsho, vol. 70, no. 5, pp. 743–747, 2012. View at Google Scholar
  77. J. Y. Yang, M. Q. Yang, H. R. Arabnia, and Y. Deng, “Genomics, molecular imaging, bioinformatics, and bio-nano-info integration are synergistic components of translational medicine and personalized healthcare research,” BMC Genomics, vol. 9, supplement 2, article I1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. G. S. Ginsburg and H. F. Willard, “Genomic and personalized medicine: foundations and applications,” Translational Research, vol. 154, no. 6, pp. 277–287, 2009. View at Publisher · View at Google Scholar
  79. G. H. Fernald, E. Capriotti, R. Daneshjou, K. J. Karczewski, and R. B. Altman, “Bioinformatics challenges for personalized medicine,” Bioinformatics, vol. 27, no. 13, pp. 1741–1748, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Li, Z. Zhang, J. Rosenzweig, Y. Y. Wang, and D. W. Chan, “Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer,” Clinical Chemistry, vol. 48, no. 8, pp. 1296–1304, 2002. View at Google Scholar · View at Scopus
  81. E. Abrahams, G. S. Ginsburg, and M. Silver, “The personalized medicine coalition: goals and strategies,” American Journal of PharmacoGenomics, vol. 5, no. 6, pp. 345–355, 2005. View at Publisher · View at Google Scholar · View at Scopus